Art. -Nr.: HY-N0691

Schisandrin

Name: Schisandrin
Brand: MedChemExpress
SKU: HY-N0691
Price: 50.00 USD
Availability: InStock
Rating: 5 (4 reviews)

(Synonyms: Schizandrin; Schizandrol; Schizandrol-A)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Schisandrin (Schizandrin), a dibenzocyclooctadiene lignan, is isolated from the fruit of Schisandra chinensis Baill. Schisandrin exhibits antioxidant, hepatoprotective, anti-cancer and anti-inflammatory activities. Schisandrin also can reverses memory impairment in rats.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.91%
CAS. Nr.: 7432-28-2
Formel: C₂₄H₃₂O₇
Molecular Weight:432.51

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Schisandrin Chemical Structure

CAS. Nr.: 7432-28-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (1)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	20.7 μM Compound: Schizandrin	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 18063366]
A549	IC₅₀	21.65 μM Compound: 1	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29501940]
A549	IC₅₀	8.5 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
DU-145	IC₅₀	13.09 μM Compound: 1	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29501940]
DU-145	IC₅₀	5.38 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
H9	IC₅₀	>58 μM Compound: schisandrin	Cytotoxicity against human H9 cells after 4 days Cytotoxicity against human H9 cells after 4 days	[PMID: 17190445]
HCT-15	IC₅₀	50.2 μM Compound: Schizandrin	Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay	[PMID: 18063366]
HEK293	IC₅₀	80.47 μM Compound: 1	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
HEK293	IC₅₀	81.74 μM Compound: 1	Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay	[PMID: 29501940]
HeLa	IC₅₀	>100 μM Compound: 5	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23237974]
HeLa	IC₅₀	28.56 μM Compound: 1	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29501940]
HeLa	IC₅₀	5.06 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
HL60/ADR	IC₅₀	0.5 ng/mL Compound: Schisandrol A	TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1) TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1)	[PMID: 17129588]
HL60/ADR	IC₅₀	3135 ng/mL Compound: Schisandrol A	TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1) TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1)	[PMID: 17129588]
HL60/ADR	IC₅₀	54 ng/mL Compound: Schisandrol A	TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1) TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1)	[PMID: 17129588]
K562	IC₅₀	25 μM Compound: Schizandrin	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 18063366]
Lewis lung carcinoma cell line	IC₅₀	>100 μM Compound: 5	Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay	[PMID: 23237974]
MCF7	IC₅₀	32.56 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29501940]
MDA-MB-231	IC₅₀	61.5 μM Compound: Schizandrin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 18063366]
SK-HEP1	IC₅₀	71.3 μM Compound: Schizandrin	Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay	[PMID: 18063366]
SMMC-7721	IC₅₀	>100 μM Compound: 5	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 23237974]
SNU-638	IC₅₀	21.1 μM Compound: Schizandrin	Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay	[PMID: 18063366]
T47D	IC₅₀	19.8 μM Compound: Schizandrin	Antiproliferative activity against human T47D cells after 72 hrs by SRB assay Antiproliferative activity against human T47D cells after 72 hrs by SRB assay	[PMID: 18063366]
U-87MG ATCC	IC₅₀	>100 μM Compound: 5	Cytotoxicity against human U87 cells after 72 hrs by MTT assay Cytotoxicity against human U87 cells after 72 hrs by MTT assay	[PMID: 23237974]

In Vitro

Schisandrin (10-100 μM; pretreated for 2 h) inhibits LPS-stimulated NO production, iNOS protein and mRNA expression in a dose-dependent manner in RAW 264.7 cells^[1].
Schisandrin (25-100 μM; pretreated for 2 h) inhibits prostaglandin E2 production, COX-2 protein and mRNA expression in LPS-stimulated RAW 264.7 macrophages^[1].
Schisandrin inhibits the SK-HEP-1, SNU-638, and T47D cells proliferation, with IC₅₀s of 42.0, 53.1, and 40.0 μM, respectively^[3].
Schisandrin (10-60 μM; 48 h) enhances Doxorubicin -induced apoptosis and selectively reverses MCF-7/DOX resistance^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[1]

View Protocol

Cell Line:

RAW 264.7 macrophages
Concentration:

12.5, 25, 50, 100 μM
Incubation Time:

Pretreated for 2 h and then incubated with LPS (1 μg/mL) for 18 h
Result:

Markedly decreased iNOS protein expression a dose-dependent manner.
Significantly inhibited COX-2 protein expression.

In Vivo

Schisandrin (10-100 mg/kg; a single i.p.) inhibits acetic acid-induced peritoneal vascular permeability and reduces the carrageenan-induced paw edema of mice^[1].
Schisandrin (1-10 mg/kg; a single p.o.) significantly reverses the Scopolamine-induced impairment of spatial memory and passive avoidance response, and enhances tremors induced by Oxotremorine in rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male ICR mice (4-weeks) were treated with λ-carrageenan by intraperitoneal injection into the right hind paw^[1]
Dosage:

100, 200 mg/kg
Administration:

A single i.p.
Result:

Inhibited paw edema by 33.43 % (100 mg/kg) and 57.38 % (200 mg/kg) at 3 h.

Chemical Information

CAS. Nr. 7432-28-2
Appearance Solid
Molecular Weight 432.51
Formel C₂₄H₃₂O₇
Color White to light yellow
SMILES

O[C@]1(C)[C@@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C3=C(OC)C(OC)=C(OC)C=C3C1
Synonyms

Schizandrin; Schizandrol; Schizandrol-A
Structure Classification
- Phenylpropanoids
- Lignans
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All Cell Proliferation/Viability AssayRT-PCRWBApoptosis AnalysisBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Enhanced Glycolysis-Driven Histone H3K18 Lactylation Regulates Epileptogenesis by Modulating the E3 Ubiquitin Ligase COP1. [Abstract]

2026 May 29:e16985. PMID: 42210782
Eur J Pharmacol

Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer. [Abstract]

2019 Jul 15:855:10-19. PMID: 31028739
Int Immunopharmacol

Schisandrin treatment suppresses the proliferation, migration, invasion, and inflammatory responses of fibroblast-like synoviocytes from rheumatoid arthritis patients and attenuates synovial inflammation and joint destruction in CIA mice. [Abstract]

2023 Sep:122:110502. PMID: 37390648
J Ovarian Res

Exploring the mechanism of Schisandra rubriflora in the treatment of polycystic ovary syndrome based on network pharmacology and molecular docking. [Abstract]

2025 Jan 28;18(1):16. PMID: 39875917

Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]

The viability of KGN cells treated with Schisandrin at different concentrations (0, 1.25, 2.5, 5, 10 and 20 µM) for 24 h was detected by CCK-8 method.

Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]

The mRNA expression levels of IL-1β, IL-6 and iNOS in KGN cells were detected by RT-qPCR treated with Schisandrin (20 μM).

Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]

The protein expression levels of Bcl-2 and Bax were detected by Western blot treated with Schisandrin (20 μM).

Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]

Apoptosis was assessed by flow cytometry treated with Schisandrin (20 μM).

Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]

The levels of MDA and SOD were detected by the corresponding detection kit treated with Schisandrin (20 μM).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 200 mg/mL (462.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3121 mL

11.5604 mL

23.1209 mL

5 mM

0.4624 mL

2.3121 mL

4.6242 mL

10 mM

0.2312 mL

1.1560 mL

2.3121 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.28 mg/mL (0.65 mM); Clear solution

This protocol yields a clear solution of ≥ 0.28 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (2.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Signal Pathway Related

Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Guo LY, et, al. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol. 2008 Sep 4;591(1-3):293-9. [Content Brief]

[2]. Egashira N, et, al. Schizandrin reverses memory impairment in rats. Phytother Res. 2008 Jan;22(1):49-52. [Content Brief]

[3]. Min HY, et, al. Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells. Bioorg Med Chem Lett. 2008 Jan 15;18(2):523-6. [Content Brief]

[4]. Zhang ZL, et, al. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Breast Cancer. 2018 Mar;25(2):233-242. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3121 mL	11.5604 mL	23.1209 mL	57.8021 mL
	5 mM	0.4624 mL	2.3121 mL	4.6242 mL	11.5604 mL
	10 mM	0.2312 mL	1.1560 mL	2.3121 mL	5.7802 mL
	15 mM	0.1541 mL	0.7707 mL	1.5414 mL	3.8535 mL
	20 mM	0.1156 mL	0.5780 mL	1.1560 mL	2.8901 mL
	25 mM	0.0925 mL	0.4624 mL	0.9248 mL	2.3121 mL
	30 mM	0.0771 mL	0.3853 mL	0.7707 mL	1.9267 mL
	40 mM	0.0578 mL	0.2890 mL	0.5780 mL	1.4451 mL
	50 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1560 mL
	60 mM	0.0385 mL	0.1927 mL	0.3853 mL	0.9634 mL
	80 mM	0.0289 mL	0.1445 mL	0.2890 mL	0.7225 mL
	100 mM	0.0231 mL	0.1156 mL	0.2312 mL	0.5780 mL

Bioz

Keywords

Schisandrin

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Schisandrin

Publications Citing Use of MedChemExpress (MCE) Schisandrin